Devyser Diagnostics AB

DVYSR

SE0016588867

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 16:13:39 31/05/2024 BST			5-day change	1st Jan Change
104.5 ^SEK	+2.96%		+1.95%	+32.95%

05-27	Devyser Wins Tender for Thalassemia in Italy	CI
05-14	Devyser Diagnostics AB Appoints Thomas Eklund as Member of the Board of Directors	CI

Devyser Diagnostics AB Appoints Thomas Eklund as Member of the Board of Directors

May 14, 2024 at 01:30 pm

Devyser Diagnostics AB (publ) announced that at the Annual General Meeting held on 14 May 2024 Thomas Eklund was elected as new member of the Board of Directors for the same period.

Latest news about Devyser Diagnostics AB

Devyser Wins Tender for Thalassemia in Italy	05-27	CI
Devyser Diagnostics AB Appoints Thomas Eklund as Member of the Board of Directors	05-14	CI
Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024	05-08
Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Devyser Receives IVDR Approval for Post-Transplant Monitoring Software	04-25	CI
Devyser Diagnostics AB Enters into Co-Marketing Agreement with Hamilton Bonaduz AG	04-23	CI
Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test	03-11	CI
Devyser Diagnostics AB Announces Study Publication Demonstrating dd-cfDNA Detection in Dual Donor Kidney Transplant Patient	02-29	CI
Transcript : Devyser Diagnostics AB, Q4 2023 Earnings Call, Feb 20, 2024	02-20
Devyser Diagnostics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-20	CI
Devyser Diagnostics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-20	CI
Devyser Diagnostics AB Announces Michael Uhlin, CSO Joins Management Team as of February 1, 2024	01-29	CI
Devyser's US Lab Inks SEK25 Million Deal with UK Diagnostics Company Cyted	01-17	MT
Devyser Genomic Laboratories Signs First Commercial Agreement with Cyted	01-17	CI
Sweden’s Devyser Wins SEK1.5 Million Tender in Italy for Cystic Fibrosis Test Kits	01-15	MT
Devyser Diagnostics AB Wins Tender for Cystic Fibrosis in Italy	01-15	CI
Devyser Diagnostics Teams Up with Illumina to Offer IVD Tests in Europe, US	01-08	MT
Devyser Diagnostics AB Signs in Vitro Diagnostic Agreement with Illumina to Broaden Access to Its Tests	01-08	CI
Sweden’s Devyser Wins $6 Million Tender for Cystic Fibrosis Diagnostic Tool in Italy	12-11	MT
Devyser Wins Approximately SEK 2 Million Tender for Cystic Fibrosis	12-11	CI
Devyser Diagnostics Bags Non-invasive Fetal RHD Test Tender in Wales	12-05	MT
Devyser wins tender for non-invasive fetal RHD testing in Wales	12-05	CI
Transcript : Devyser Diagnostics AB, Q3 2023 Earnings Call, Nov 09, 2023	11-09
Devyser Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Devyser and Thermo Fisher Scientific Collaborate to Promote Laboratory Services to Advance Pharmaceutical Research	13/09/23	CI

Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnosticsâ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.

Sector

Biotechnology & Medical Research

Calendar

23/07/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Devyser Diagnostics AB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

68.22 DKK

Average target price

80.62 DKK

Spread / Average Target

+18.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DEVYSER DIAGNOSTICS AB	+32.95%	162M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research